news-details
Health,Watchlist,healthcare stocks

5 HealthTech Stocks Trending Now

Powered by HealthTechMovers.com

According to healthtechmovers.com, there are a few energy stocks that have appeared to be trending from recent buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding them to their watchlist.

 Inspire Medical Systems, INSP
Summary: Inspire Medical Systems Inc. is a medical technology company. It focused on the development and commercialization of solutions for obstructive sleep apnea. The company's proprietary Inspire therapy is a neurostimulation technology which provides treatment for moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc.is based in Minnesota, United States.
Richard Newitter analyst at Truist Financial reiterates coverage on Inspire Medical Systems (INSP) in the health sector with a Buy rating and has set a price target of $ 250.

TipRanks.com reports that Inspire Medical Systems currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $282.50. 

In addition, TradingView issued a Sell rating for INSP over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on INSP.

For the complete breakdown on INSP, please click here >>

 Seres Therapeutics, MCRB
Summary: Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Vernon Bernardino analyst at H.C. Wainwright reiterates coverage on Seres Therapeutics (MCRB) in the health sector with a Buy rating and has set a price target of $ 25.

TipRanks.com reports that Seres Therapeutics currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $16.00. 

In addition, TradingView issued a Sell rating for MCRB over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MCRB.

For the complete breakdown on MCRB, please click here >>

 PDS Biotechnology, PDSB
Summary: PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary Versamune(R) platform technology, which activates and directs the human immune system. PDS Biotechnology Corp, formerly known as Edge Therapeutics Inc., is based in Berkeley Heights, United States.
Robert LeBoyer analyst at Noble Financial reiterates coverage on PDS Biotechnology (PDSB) in the health sector with a Buy rating and has set a price target of $ 22.

TipRanks.com reports that PDS Biotechnology currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $20.67. 

In addition, TradingView issued a Strong Sell rating for PDSB over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on PDSB.

For the complete breakdown on PDSB, please click here >>

 Aldeyra Therapeutics, ALDX
Summary: Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.
Justin Kim analyst at Oppenheimer reiterates coverage on Aldeyra Therapeutics (ALDX) in the health sector with a Buy rating and has set a price target of n/a.

TipRanks.com reports that Aldeyra Therapeutics currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $23.75. 

In addition, TradingView issued a Buy rating for ALDX over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ALDX.

For the complete breakdown on ALDX, please click here >>

 Adicet Bio, ACET
Summary: Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.
Soumit Roy analyst at JonesTrading reiterates coverage on Adicet Bio (ACET) in the health sector with a Buy rating and has set a price target of $ 25.

TipRanks.com reports that Adicet Bio currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $28.86. 

In addition, TradingView issued a Neutral rating for ACET over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ACET.

For the complete breakdown on ACET, please click here >>



MarketMoversInsider.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE.

One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals.  TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>

MarketMoversInsider.com is for serious traders.

Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.    
==============================================================================